Ascentage Pharma Group International
AAPG24.520USD
+0.330+1.36%
Cierre 02/06, 16:00（ET）Cotizaciones retrasadas 15 min
0.00Cap. mercado
--P/E TTM
Más Datos de Ascentage Pharma Group International Compañía
Ascentage Pharma Group International is an investment holding company primarily engaged in the discovery, development, and commercialization of therapies for hematologic malignancies. The Company's main products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), APG-5918, and APG-2449. The Company's products are primarily used to treat chronic myeloid leukemia (CML), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), and multiple myeloma (MM). The Company primarily conducts its businesses in domestic market.
Información de Ascentage Pharma Group International
Símbolo de cotizaciónAAPG
Nombre de la empresaAscentage Pharma Group International
Fecha de salida a bolsaOct 28, 2019
Director ejecutivoYang (Dajun)
Número de empleados- -
Tipo de seguridadDepository Receipt
Fin del año fiscal- -
Dirección68 Xinqing Road, Suzhou Industrial Park
CiudadSUZHOU
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísChina
Código postal- -
Teléfono
Sitio Webhttps://www.ascentage.cn/
Símbolo de cotizaciónAAPG
Fecha de salida a bolsaOct 28, 2019
Director ejecutivoYang (Dajun)
Ejecutivos de Ascentage Pharma Group International
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Dajun Yang, M.D., Ph.D.
Dr. Dajun Yang, M.D., Ph.D.
Executive Chairman of the Board, Chief Executive Officer, Co-Founder
Executive Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Shaomeng Wang, Ph.D.
Dr. Shaomeng Wang, Ph.D.
Non-Executive Director, Co-Founder
Non-Executive Director, Co-Founder
--
--
Dr. Dazhong (Simon) Lu, Ph.D.
Dr. Dazhong (Simon) Lu, Ph.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Changqing Ye
Mr. Changqing Ye
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Wei Ren
Mr. Wei Ren
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Dr. David Sidransky, M.D.
Dr. David Sidransky, M.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Dr. Yifan Zhai, M.D., Ph.D.
Dr. Yifan Zhai, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Raymond Jeffrey (Jeff) Kmetz
Mr. Raymond Jeffrey (Jeff) Kmetz
Chief Business Officer
Chief Business Officer
--
--
Mr. Thomas Joseph (Tom) Knapp, J.D.
Mr. Thomas Joseph (Tom) Knapp, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
--
--
Ms. Marina S. Bozilenko
Ms. Marina S. Bozilenko
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Dajun Yang, M.D., Ph.D.
Dr. Dajun Yang, M.D., Ph.D.
Executive Chairman of the Board, Chief Executive Officer, Co-Founder
Executive Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Shaomeng Wang, Ph.D.
Dr. Shaomeng Wang, Ph.D.
Non-Executive Director, Co-Founder
Non-Executive Director, Co-Founder
--
--
Dr. Dazhong (Simon) Lu, Ph.D.
Dr. Dazhong (Simon) Lu, Ph.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Changqing Ye
Mr. Changqing Ye
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Wei Ren
Mr. Wei Ren
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Dr. David Sidransky, M.D.
Dr. David Sidransky, M.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Desglose de ingresos
La empresa aún no ha revelado los datos relevantes.
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: mar., 20 de ene
Actualizado: mar., 20 de ene
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
XY Capital Ltd.
0.02%
Point72 (DIFC) Ltd
0.02%
NEOS Investment Management, LLC
0.01%
Citadel Advisors LLC
0.01%
Otro
99.94%
Accionistas
Accionistas
Proporción
XY Capital Ltd.
0.02%
Point72 (DIFC) Ltd
0.02%
NEOS Investment Management, LLC
0.01%
Citadel Advisors LLC
0.01%
Otro
99.94%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
0.06%
Hedge Fund
0.01%
Otro
99.93%
Participación institucional
Actualizado: lun., 8 de dic
Actualizado: lun., 8 de dic
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
24
69.78K
0.07%
-205.06K
2025Q3
23
89.21K
0.29%
+6.09K
2025Q2
16
82.77K
0.27%
-154.43K
2025Q1
6
237.19K
0.00%
+237.19K
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
XY Capital Ltd.
18.12K
0.02%
+12.53K
+224.15%
Sep 30, 2025
Point72 (DIFC) Ltd
17.93K
0.02%
-2.96K
-14.17%
Sep 30, 2025
NEOS Investment Management, LLC
10.38K
0.01%
-5.11K
-32.98%
Sep 30, 2025
Citadel Advisors LLC
9.65K
0.01%
+9.65K
--
Sep 30, 2025
UBS Financial Services, Inc.
18.34K
0.02%
+10.99K
+149.35%
Sep 30, 2025
Mirae Asset Global Investments (USA) LLC
2.46K
0%
+2.46K
--
Sep 30, 2025
Tower Research Capital LLC
829.00
0%
+829.00
--
Sep 30, 2025
Geode Capital Management, L.L.C.
361.00
0%
--
--
Nov 30, 2025
Osaic Holdings, Inc.
220.00
0%
+220.00
--
Sep 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
Tema Oncology ETF
0.43%
Invesco Golden Dragon China ETF
0%
Tema Oncology ETF
Proporción0.43%
Invesco Golden Dragon China ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
